Nexalin Technology, Inc. (NXL) stock
NXLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
$1.44−0.06 (-4.00%)
Close on Nov 18, 2026Market cap $31.73MP/E –Yield –
Nexalin Technology r&d expenses
Research and development expenses are spending on new products and technology.
Nexalin Technology's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.36M, down 12.0% year over year. For fiscal 2025 it was $1.08M, down 9.0% from the year before. The highest annual figure on record is $1.92M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08M | -9.0% |
| FY2024 | Dec 31, 2024 | $1.19M | -38.0% |
| FY2023 | Dec 31, 2023 | $1.92M | +276.1% |
| FY2022 | Dec 31, 2022 | $511.00K | +267.6% |
| FY2021 | Dec 31, 2021 | $139.00K | -90.7% |
| FY2020 | Dec 31, 2020 | $1.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $564.48K | +150.0% |
| Q1 FY2026 | Mar 31, 2026 | $346.38K | -14.7% |
| Q4 FY2025 | Dec 31, 2025 | $224.94K | -69.5% |
| Q3 FY2025 | Sep 30, 2025 | $226.52K | +26.9% |
| Q2 FY2025 | Jun 30, 2025 | $225.77K | +33.3% |
| Q1 FY2025 | Mar 31, 2025 | $406.29K | +284.5% |
| Q4 FY2024 | Dec 31, 2024 | $737.24K | +405.0% |
| Q3 FY2024 | Sep 30, 2024 | $178.57K | +171.2% |
| Q2 FY2024 | Jun 30, 2024 | $169.41K | -52.5% |
| Q1 FY2024 | Mar 31, 2024 | $105.67K | -7.0% |
| Q2 FY2023 | Jun 30, 2023 | $146.00K | +394.2% |
| Q1 FY2023 | Mar 31, 2023 | $65.83K | +469.2% |
| Q4 FY2022 | Dec 31, 2022 | $356.28K | +1192.7% |
| Q3 FY2022 | Sep 30, 2022 | $113.62K | +239.4% |
| Q2 FY2022 | Jun 30, 2022 | $29.54K | – |
| Q1 FY2022 | Mar 31, 2022 | $11.57K | – |
| Q4 FY2021 | Dec 31, 2021 | $27.56K | – |
| Q3 FY2021 | Sep 30, 2021 | $33.47K | – |
See a number that looks wrong?